Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebound ...More

Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the previous quarter. The results included a Rs 20 crore gratuity credit and a Rs 25 crore exceptional loss from employee termination benefits, alongside management changes. ...Less

The company attributed the drop in net profit to depreciation, amortisation and interest increase of Rs 3 ...More

The company attributed the drop in net profit to depreciation, amortisation and interest increase of Rs 353 crore over last year primarily related to the biosimilar business acquisition cost. ...Less

Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs Rs 977 crore in Q1 ...More

Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs Rs 977 crore in Q1FY23, while the generic business rose 19% to Rs 580 crore.Biocon said that its net profit and margins would have been much higher, had it not been for higher R&D and other expenses. ...Less

Consolidated total income of the company stood at Rs 1,490 crore for the quarter under consideration. ...More

Consolidated total income of the company stood at Rs 1,490 crore for the quarter under consideration. ...Less

The Bengaluru-headquartered biopharma company’s revenue was up 14% at Rs 1,690 crore during the quarter. ...More

The Bengaluru-headquartered biopharma company’s revenue was up 14% at Rs 1,690 crore during the quarter. ...Less

Before accounting for the loss at Bicara, a personal therapeutic company, Biocon's profits stood at Rs 14 ...More

Before accounting for the loss at Bicara, a personal therapeutic company, Biocon's profits stood at Rs 142 crore. ...Less

Biocon's net profit for Q1FY25 surged to ₹660 crore, up from ₹101 crore the previous year, primarily due ...More

Biocon's net profit for Q1FY25 surged to ₹660 crore, up from ₹101 crore the previous year, primarily due to a one-time gain from selling Biocon Biologics' domestic branded formulation business. Revenue remained flat at ₹3,433 crore. Core EBITDA saw a decline, although overall EBITDA improved significantly due to the one-off gain. ...Less

Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increase ...More

Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3,942 crore, fueled by Biocon Biologics' 18% growth and Syngene's 11% increase. A recent QIP of Rs 4,500 crores will strengthen Biocon's balance sheet and increase its ownership in Biocon Biologics. ...Less

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 c ...More

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the company had posted a net profit of Rs 660 crore in Q3FY24, boosted by an exceptional item of Rs 566 crore. ...Less

Asian stocks inched higher on Friday, buoyed by gains in U.S. technology shares. ...More

Asian stocks inched higher on Friday, buoyed by gains in U.S. technology shares. ...Less